Role of B-Cell Inhibition in Autoimmune Hepatitis: Lessons Learnt From Systemic Lupus Erythematosus

TL;DR

A case study shows that belimumab, used for lupus, may also help treat autoimmune hepatitis when standard treatments fail.

Contribution

The study demonstrates belimumab's potential as an adjunct therapy for autoimmune hepatitis in patients with overlapping autoimmune conditions.

Findings

A patient with autoimmune hepatitis and lupus showed reduced liver enzymes after treatment with mycophenolate and belimumab.

Belimumab may reduce systemic inflammation and autoimmune activity in patients with overlapping autoimmune diseases.

Standard azathioprine therapy failed to improve liver function tests in the patient.

Abstract

Autoimmune hepatitis (AIH) is a chronic liver disease characterized by histological, clinical, and laboratory findings, including elevated liver enzymes, immunoglobulin G (IgG), and autoantibodies. Belimumab, a monoclonal antibody targeting B-lymphocyte stimulator (BLyS), is primarily approved for systemic lupus erythematosus (SLE) but shows promise in improving liver function tests (LFTs) in patients with concurrent AIH and SLE. We present the case of a 24-year-old female diagnosed with AIH and SLE, whose elevated LFTs initially resisted standard azathioprine therapy. Upon switching to mycophenolate and belimumab, a notable reduction in LFTs was observed. This case highlights belimumab’s potential as an adjunct therapy in AIH, especially in patients with overlapping autoimmune conditions, supporting its role in reducing systemic inflammation and autoimmune activity.

Figures